Only show results serving Ohio? Ok

Drug Target Technology Companies

11 companies found
  • PharmAI GmbH
    Technology
    based in Dresden, GERMANY

    PharmAI’s mission is to make early-stage drug discovery far more efficient by increasing success rates while reducing costs. The company develops groundbreaking AI-powered software for the analysis of 3D protein structures. This technology helps ...

  • DEARGEN Inc.
    Technology
    based in Daejeon, SOUTH KOREA

    We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...

    Agonist

    Agonist

    Agonist refers to substances that activate a specific target protein. It can easily be viewed as the opposite of inhibitor. Until now, Deargen's drug-target interaction (DTI) was predicted based on ...

    CONTACT SUPPLIER
  • TAE Life Sciences (TLS)
    Technology
    based in Foothill Ranch, CALIFORNIA (USA)

    TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers. Founded in 2017, TLS is the only company ...

    TAE Life Sciences - Targeted Boron Drugs

    TAE Life Sciences - Targeted Boron Drugs

    TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated ...

    CONTACT SUPPLIER
  • BellBrook Labs
    Technology
    based in Madison, WISCONSIN (USA)

    BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, we identify areas where there is a strong need but a ...

  • Taiwan Liposome Company, Ltd. (TLC)
    Technology
    based in Nangang Distric, TAIWAN

    We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...

    BioSeizer - Model LipAD - Proprietary Lipid-Assembled Drug Delivery Platforms  Technology

    BioSeizer - Model LipAD - Proprietary Lipid-Assembled Drug Delivery Platforms Technology

    TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with entirely unique properties. TLC has proprietary solution for pharmaceutical product development called LipAD®. ...

    CONTACT SUPPLIER
  • Da Zen Theranostics, Inc.
    Technology
    based in Silicon Valley, CALIFORNIA (USA)

    Da Zen Theranostics, Inc. (Da Zen) has developed revolutionary therapies for cancer detection, imaging, and treatment in order to prolong survival and improve quality of life for patients with cancer. The innovative research at Da Zen has led to the ...

    The Cancer Targeting Dye-Carrier

    The Cancer Targeting Dye-Carrier

    Circumventing drug toxicity and drug resistance is key to effective anticancer therapy. Da Zen’s products and technologies deliver targeted anticancer drugs, such as ...

    CONTACT SUPPLIER
  • STALICLA
    Technology
    based in Geneve, SWITZERLAND

    STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have ...

    STALICLA - Databased Endophenotyping Patient Identification (DEPI) Technology

    STALICLA - Databased Endophenotyping Patient Identification (DEPI) Technology

    STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches ...

    CONTACT SUPPLIER
  • CIS Pharma AG
    Technology
    based in Bubendorf, SWITZERLAND

    CIS Pharma is an innovator in the life science industry in the field of Oncology and Ophthalmolog. We were awarded with the European Frost & Sullivan Technology Innovation Award for our unique smart polymer technologyœ, says Christoph Schäfer, CEO ...

    CIS Pharma - Novel Antibody Drug Conjugates (ADCs)

    CIS Pharma - Novel Antibody Drug Conjugates (ADCs)

    CIS Pharma develops novel antibody-drug- conjugates (ADCs) based on our proprietary polymer carrier platform. Our polymers serve as carriers that are loaded with cytotoxic drugs, radioisotopes or other active ...

    CONTACT SUPPLIER
  • Sibylla Biotech S.p.A.
    Technology
    based in Verona, ITALY

    At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding ...

    Sibylla - Model PPI-FIT - Pharmacological Protein Inactivation by Folding Intermediate Targeting Technology

    Sibylla - Model PPI-FIT - Pharmacological Protein Inactivation by Folding Intermediate Targeting Technology

    The PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) technology, of which Sibylla is the exclusive licensee, is a paradigm shift in rational drug design. The basic task of ...

    CONTACT SUPPLIER
  • Genmab A/S
    Technology
    based in Copenhagen V, DENMARK

    Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...

    Genmab - Tisotumab Vedotin

    Genmab - Tisotumab Vedotin

    Tisotumab Vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.1 It is composed of Genmab’s human monoclonal antibody (mAb) that ...

    CONTACT SUPPLIER
  • Zymeworks Inc
    Technology
    based in Vancouver, BRITISH COLUMBIA (CANADA)

    Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...

    Zymeworks - Model ZW49 - Bispecific Antibody Drug Conjugate (ADC)

    Zymeworks - Model ZW49 - Bispecific Antibody Drug Conjugate (ADC)

    ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a ...

    CONTACT SUPPLIER

Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you